Objective: Short-course radiotherapy (25 Gy in 5 fractions) has been shown to be non-
inferior to standard course radiotherapy in elderly and frail patients (60 Gy in 30 fractions) …

Results: Seventy-seven patients with a median age of 53 years (range 4-76 years) showed a
median survival time (MST) of 12 months. In subgroup analyses, the PORT patients revealed …

Background: This analysis was conducted to evaluate the efficacy and safety of
temozolomide based chemotherapy in treating patients with glioma. Methods: Clinical …

Background: Glioblastoma multiform (GBM) is a highly aggressive tumor with median
survival of approximately 14 months. Management consists of maximal surgical resection …

Background: Radiotherapy combined with temozolomide chemotherapy (STUPP regimen) is
the standard treatment regimen for newly diagnosed glioblastoma (GBM). It is considered …

Results On univariate analysis, the following variables were significantly associated with
overall survival: Karnofsky Performance Status (KPS)(< 80 vs≥ 80 p= 0.039), radiation dose …

Aim: To compare the outcome of second line treatment of recurrent high-grade glioma by re-
irradiation or bevacizumab-based chemotherapy. Methods: Retrospectively, patients with …

Purpose/Objective (s) Patients 70 years old or younger with good performance status with
glioblastoma often are treated with radiotherapy (RT) over 6 weeks with concurrent and …

Objectives: There is no accepted standard of care for patients over age 70 with glioblastoma
(GBM). We began this study to describe our results and toxicities in the over 70 population …

For elderly patients with glioblastoma multiforme (GBM), radiotherapy plus concomitant and
adjuvant temozolomide has resulted in longer survival. We investigated patient performance …